Navigate with Confidence

Latest 340B Updates

From upfront discounts to rebate-based pricing—QuicksortRx gives you the tools to stay compliant, plan, and act quickly in a shifting regulatory environment.

Request your personalized analysis.

A Pilot That Could Change Everything

HRSA has approved a revised 340B Rebate Model Pilot Program, scheduled to begin January 1, 2027, though it has been challenged in court and details could change.

For covered entities, this would mean paying full WAC upfront—then waiting for rebate checks later. That delay could put significant cash flow pressures on health systems.

We built a tool to help our customers navigate the change.

 

 

340B Benefit Tool

Know the total 340B program impact—including estimated financial benefits and cash needs for all potential rebate models. See annual, monthly, and quarterly benefits, plus potential rebate exposure by your pharmacies and suppliers.

340B Rebate Pilot Report (NEW)

Pinpoint your hospital’s exposure under the revised 340B Rebate Pilot.

Know how much cash you may need to float while waiting for rebates on the pilot drugs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.

340B Rebate Pilot Report (NEW)

Pinpoint your hospital’s exposure under the revised 340B Rebate Pilot.

Know how much cash you may need to float while waiting for rebates on the pilot drugs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.

340B Rebate Pilot Report (NEW)

Pinpoint your hospital’s exposure under the revised 340B Rebate Pilot.

Know how much cash you may need to float while waiting for rebates on the pilot drugs. Get ongoing insights into IRA medication spend, WAC changes, and rebate forecasts.

Understand Your Rebate Exposure—Before It Hits.

Equip yourself to confidently advise finance leaders with insights at your fingertips.

Your customized analysis includes:

1
Pricing Data

Your pricing data showing WAC spend for every NDC in the pilot

2
Projections

Assess impact for 2026 and additional 2027 projections

3
Clear Impact

Estimated rebate lag effects on cash flow

4
Exposure

Detailed net exposure breakdown by drug and category

What's Next?

Build For What's Coming

The 340B Rebate Pilot Report is just the start. We don’t wait for policy to finalize—we build so you can act now. We’ll keep tracking HRSA and the court case, and we’re exploring real-time rebate reconciliation, increased price transparency, and future tools for inpatient and infusion workflows.